articleTop 1% cited

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

Annals of Internal Medicine · 2004 · Vol. 140(5) · pp. 346–355

Stephanos J. Hadziyannis✉(University of Göttingen)Hoel Sette(Universitätsmedizin Göttingen)Timothy R. Morgan(Universitätsmedizin Göttingen)Vijayan Balan(Universitätsmedizin Göttingen)Moises Diago(Universitätsmedizin Göttingen)Patrick Marcellin(Universitätsmedizin Göttingen)Giuliano Ramadori(Universitätsmedizin Göttingen)Henry Bodenheimer(Universitätsmedizin Göttingen)David Bernstein(Universitätsmedizin Göttingen)Mario Rizzetto(Universitätsmedizin Göttingen)Stefan Zeuzem(Universitätsmedizin Göttingen)Paul J. Pockros(Universitätsmedizin Göttingen)Amy Lin(Universitätsmedizin Göttingen)Andrew M. Ackrill(Universitätsmedizin Göttingen)for the PEGASYS International Study Group*

View via DOI Publisher page

Abstract

Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype. Patients with HCV genotype 1 require treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotypes 2 or 3 seem to be adequately treated with a low dose of ribavirin for 24 weeks.

Hepatitis C virus research Liver Disease Diagnosis and Treatment Hepatitis B Virus StudiesRibavirinMedicineInternal medicineGastroenterologyHepatitis CAlpha interferonHepatitis C virusInterferonImmunologyVirus

MeSH terms

Interferon alpha-2AdultAntiviral AgentsDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleGenotypeHumansMalePolyethylene GlycolsRecombinant ProteinsRibavirinHepacivirusInterferon-alpha

Citations

2,835

FWCI

118.35

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

EASL Recommendations on Treatment of Hepatitis C 2016